Ofatumumab

Adult: In combination with chlorambucil in previously untreated patients for whom fludarabine-based treatment is inappropriate: Cycle 1: Initially, 300 mg on day 1, followed by 1,000 mg on day 8. Subsequent cycles: 1,000 mg on day 1 every 28 days; continue for at least 3 cycles until best response is achieved or a Max of 12 cycles. In combination with fludarabine and cyclophosphamide in patients with relapsed case: Cycle 1: Initially, 300 mg on day 1, followed by 1,000 mg on day 8. Subsequent cycles: 1,000 mg on day 1 every 28 days; continue for a Max of 6 cycles. For extended treatment of patients who are in complete or partial response following at least 2 lines of therapy for recurrent or progressive case: Initially, 300 mg on day 1, followed by 1,000 mg on day 8, followed by 1,000 mg 7 weeks later; then every 8 weeks thereafter for up to Max of 2 years. Initial doses are infused at 12 mL/hr; subsequent doses at 25 mL/hr. In combination with fludarabine and alemtuzumab in patients with refractory CLL (total of 12 doses): Initially, 300 mg on day 1, followed 1 week later by 2,000 mg once weekly for 7 doses (doses 2-8); followed 4 weeks later by 2,000 mg once every 4 weeks for 4 doses (doses 9-12). 1st and 2nd doses are infused at 12 mL/hr; 3rd through 12th doses at 25 mL/hr. Infusion rates may be adjusted according to safety and tolerability (refer to detailed product guideline). Premedicate with paracetamol, antihistamine, and corticosteroid before each administration. Treatment recommendations may vary among individual products and between countries. Refer to specific product guidelines.

Adult: Initially, 20 mg once weekly for 3 doses (weeks 0, 1, and 2). Maintenance: 20 mg once a month, starting at week 4. Treatment recommendations may vary among individual products and between countries (refer to specific product guidelines).